Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious
NCT ID: NCT01251939
Last Updated: 2012-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2011-10-31
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment with ibuprofen
Gestational age \<32 weeks and \<1500 g, postnatal age older than 48 hours and echocardiographic evidence of hemodynamically significant PDA
Near-infrared spectroscopy (NIRS)
Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.
Controls
Gestational age \<32 weeks and \<1500 g, postnatal age older than 48 hours and without significant PDA
Near-infrared spectroscopy (NIRS)
Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Near-infrared spectroscopy (NIRS)
Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Echocardiographic evidence of hemodynamically significant patent ductus arterious
Exclusion Criteria
* Intraventricular hemorrhage of grade 3 within the previous 24 hours
* Serum creatinine level 1.5 mg%,serum urea nitrogen concentration \>50 mg%,
* Platelet count 60 000/mL3, a tendency to bleed (defined by the presence of hematuria, blood in the endotracheal aspirate, gastric aspirate, or stools and/or oozing from puncture sites)
* Hyperbilirubinemia necessitating exchange transfusion
2 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zekai Tahir Burak Women's Health Research and Education Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nilufer Guzoglu
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nilufer Guzoglu
Role: PRINCIPAL_INVESTIGATOR
Zekai Tahir Burak Women's Health Research and Education Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zekai Tahir Burak Maternity and Teaching Hospital
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
n7860088
Identifier Type: -
Identifier Source: org_study_id